Kymera Therapeutics EPS KYMR

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Kymera Therapeutics' earnings per share was −$3.24 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.62.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.62	n/a	−$3.24
Q1 FY26	Mar 31, 2026	−$0.71	n/a	−$3.57
Q4 FY25	Dec 31, 2025	−$0.97	n/a	−$3.68
Q3 FY25	Sep 30, 2025	−$0.94	n/a	−$3.59
Q2 FY25	Jun 30, 2025	−$0.95	n/a	−$3.47
Q1 FY25	Mar 31, 2025	−$0.82	n/a	−$3.10
Q4 FY24	Dec 31, 2024	−$0.88	n/a	−$2.97
Q3 FY24	Sep 30, 2024	−$0.82	n/a	−$2.34
Q2 FY24	Jun 30, 2024	−$0.58	n/a	−$2.42
Q1 FY24	Mar 31, 2024	−$0.69	n/a	−$2.51
Q4 FY23	Dec 31, 2023	−$0.25	n/a	−$2.52
Q3 FY23	Sep 30, 2023	−$0.90	n/a	−$2.87

Companies in Biotechnology nearest Kymera Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
KYMRKymera Therapeutics	−$3.24
KRYSKrystal Biotech	$7.98	+62% a year
RGENRepligen	$0.73
TECHBIO-TECHNE	$1.15	+150% a year
HALOHalozyme Therapeutics	$3.35	−23% a year
NBIXNeurocrine Biosciences	$6.82	+102% a year
EXELExelixis	$3.18	+53% a year
INCYIncyte	$7.85	+78% a year
UTHRUnited Therapeutics	$27.95	+9% a year
ALNYAlnylam Pharmaceuticals	$5.93
ADMAAdma Biologics	$0.70	−18% a year
Peer median	$4.64